CE

Chuka Esiobu

Principal at Define Ventures

San Francisco, California

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Education

Work Experience

  • Principal

    2024

    Partnering with entrepreneurs who are redefining healthcare.

  • Investor

    2020 - 2024

    MBA Associate (2020-2021) | Investor (2021-2024)

  • Associate Intern

    2019 - 2020

  • Summer Associate

    2019 - 2019

    Due diligence on live venture capital and growth equity deals Sourcing and market roadmap development for companies across the healthcare landscape

2018 - 2019

  • Associate Director

    2019 - 2019

    M&A targeting, due diligence, and business case development Strategy and product development/project management for new industry-leading, value-based care initiatives touching over 3M patients in EVH network

  • Senior Analyst

    2018 - 2018

  • Associate

    2016 - 2018

    Corporate development and strategy consulting for healthcare, tech, and public sector clients

2015 - 2016

  • Business Development Manager

    2015 - 2016

    (Part-time) Partnered with CEO to re-structure the start-up's operations, pricing, and incentives; built business plan, sourced clients, expanded offerings, and recruited/trained city managers

  • Researcher

    2015 - 2016

    Conducted independent research in the Kevin Eggan Lab exploring the genetic underpinnings of ALS utilizing stem cell methods; research paper submitted towards completion of an honors thesis

2015 - 2015

  • Associate Consultant Intern

    2015 - 2015

    Conducted market analysis and competitive benchmarking as a member of the firm’s Private Equity Group (PEG)

  • Chair of Health Policy Group

    2014 - 2014

    Co-led team commissioned by Sen. Kennan to improve state policy; generated recommendations for passed Senate bill: “An Act to Increase Opportunities for Long-Term Substance Abuse Recovery”

  • Lab Intern

    2013 - 2013

    Conducted malaria research in the Wirth Lab and at a partner institution in Dakar as a recipient of the Harvard Global Health Institute's Young Leaders in Global Health scholarship